fatty liver


Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.fatty liver - yellow discoloration as a result of the accumulation of certain fats (triglycerides) in the liver; can be caused by alcoholic cirrhosis or pregnancy or exposure to certain toxins
liver disease - a disease affecting the liver
References in periodicals archive ?
Our results suggest that resveratrol act as a bioregulator for some biochemical parameters in fructose induced non-alcoholic fatty liver.
Objective: To compare serum lipid profile in different ultrasonographic grades of non alcoholic fatty liver disease (NAFLD).
According to Reuters on Friday, a type of fatty liver disease that is not related to excess drinking has exhibited greater brain shrinkage than what normally happens with age.
It was found that moderate and vigorous exercise equally were effective in reducing intrahepatic triglyceride content among patients with nonalcoholic fatty liver disease.
We aimed to explore the effects of PUFA supplementation in patients with non-alcoholic fatty liver disease (NAFLD).
I was quite shocked when neither the radiologist nor the doctor explained me what this fatty liver was except that consider it near normal" said Mrs.
Non-Alcoholic Fatty Liver Disease (NAFLD) is defined as histopathological fat accumulation of > 5% of the liver weight.
adults suffer from non-alcoholic fatty liver disease (NAFLD), in which fat builds up in the liver despite little or no alcohol intake.
A multimodal research process has provided clues to the role of angiogenesis in the etiology of nonalcoholic fatty liver disease (NAFLD) and its more serious cousin, nonalcoholic steatohepatitis (NASH).
Lee Kang Hoe, senior consultant at the Asian American Liver Center-Gleneagles Singapore, likened a fatty liver to hypertension-both are silent killers.
a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the first patient has been dosed in the company's Phase 2 clinical trial of VK2809 in patients with primary hypercholesterolemia and non-alcoholic fatty liver disease.